Impact of Concomitant Methotrexate Use and Prior Biologic Disease‐Modifying Antirheumatic Drug Exposure on Tofacitinib Efficacy and Safety in Patients with Polyarticular Course Juvenile Idiopathic Arthritis: Post Hoc Analysis of a Phase 3 Randomized Withdrawal Trial

Objective We evaluate tofacitinib efficacy and safety in patients with juvenile idiopathic arthritis (JIA) stratified by concomitant methotrexate and prior biologic disease‐modifying antirheumatic drug (bDMARD) treatment. Methods In this two part, double‐blind, randomized withdrawal Phase 3 trial (N...

Полное описание

Библиографические подробности

Главные авторы:	Nicolino Ruperto, Daniel J. Lovell, Olga Synoverska, Carlos Abud‐Mendoza, Alberto Spindler, Yulia Vyzhga, Iris Reyhan, Lyudmila Grebenkina, Irit Tirosh, Lisa Imundo, Peter Chiraseveenuprapund, Daniel J Kingsbury, Betul Sozeri, Sheetal S. Vora, Sampath Prahalad, Elena Zholobova, Kevin D. Roberts, Gosford Sawyerr, Andreas Blum, Andrea Shapiro, Annette Diehl, Abbas Ebrahim, Pascal Klaus, Alberto Martini, Hermine I. Brunner, for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Wiley 2025-10-01
Серии:	ACR Open Rheumatology
Online-ссылка:	https://doi.org/10.1002/acr2.70097
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!